摘要
目的 探讨少腹逐瘀颗粒在调节子宫内膜异位症患者子宫内膜容受性中作用及其意义。方法 取2018年01月至2020年12月在本院手术治疗EMs的患者82例,术后根据患者意愿分中药组、对照组两组, 中药组术后给予少腹逐瘀颗粒口服2疗程,再次超声监测子宫内膜容受性相关指标,随访妊娠率;对照组术后同一时间给予上述超声。结果 中药组与其术前比较,VI、FI无统计学差异(P>0.05),子宫内膜的厚度、子宫内膜的容积、PI、RI、S/D、VFI、均有统计学差异(P<0.05);中药组和对照组比较,子宫内膜的容积、子宫内膜的厚度、VI、FI、VFI均无统计学差异(P>0.05),PI、RI有统计学差异(P<0.05)。结论 手术治疗有助于EMs患者的子宫内膜容受性相关指标的正向改善,如降低内膜血流阻力和增加内膜下血流灌注;少腹逐瘀颗粒对EMs术后患者的内膜下血流灌注的改善有一定作用。
关键词: 少腹逐瘀颗粒;子宫内膜异位症;子宫内膜容受性
Abstract
Objective To explore the role and significance of Shaofu Zhuyu Granule in regulating endometrial receptivity in patients with endometriosis. Methods: 82 patients with EMS who underwent surgery in our hospital from January 2018 to December 2020 were divided into two groups: Traditional Chinese medicine group and control group according to the wishes of the patients. The traditional Chinese medicine group was given Shaofu Zhuyu Granule orally for two courses after operation. The indexes related to endometrial receptivity were monitored by ultrasound again, and the pregnancy rate was followed up; The control group was given the above ultrasound at the same time after operation. Results: There was no significant difference in VI and fi between the traditional Chinese medicine group and its preoperative group (P > 0.05), but there were significant differences in endometrial thickness, endometrial volume, PI, RI, S / D, VFI and (P < 0.05); Compared with the control group, there was no significant difference in endometrial volume, endometrial thickness, VI, FI and VFI (P > 0.05), but there was significant difference in PI and RI (P < 0.05). Conclusion : surgical treatment contributes to the positive improvement of endometrial receptivity in patients with EMS, such as reducing endometrial blood flow resistance and increasing subendometrial blood perfusion; Shaofu Zhuyu Granule has a certain effect on the improvement of subintimal blood perfusion in patients with EMs.
Key words: Shaofu Zhuyu Granule; Endometriosis; Endometrial receptivity
参考文献 References
[1] Meuleman C, Vandenabeele B, Fieuws S, et al., High prevalence of endometriosis in infertile women with normal ovulation and normospermic partners[J]. Fertil Steri, 2009;(92): 68-74.
[2] 刘敏,吴艳婷,金志春等,中医药改善子宫内膜容受性作用研究[J]. 山西中医,2018; 34(2):53-56.
[3] 刘彤鸥,余俊,丹萸饮对不明原因性不孕患者子宫内膜容受性影响的研究[J].时珍国医国药,2021;32(9): 2205-2207.
[4] 郑 婧,王必勤,丁 霞等,中药序贯疗法成功助孕反复IVF-ET失败6次病案1例[J].中国中医基础医学杂,2021,27(03):520-521.
[5] 梁莉,武权生,张小花,少腹逐瘀汤治疗寒凝血瘀型子宫内膜异位症痛经研究进展[J].时珍国医国药,2021,32(02):437-440.
[6] 何瑞琪,黄灿灿,张小花,少腹逐瘀汤联合西药治疗子宫内膜异位症的Meta分析[J].山东中医杂志,2021;40 (11):1214-1221.
[7] 张腾飞,茅菲,赵建龙,少腹逐瘀汤治疗子宫内膜异位症对患者子宫内膜受容性及血清RBP4、HMGB1、MCP-1、RANTES的影响[J].中药材,2021;(01): DOI:10.13863/j.issn1001-4454.2021.01.040.
[8] 李 琳,贺 冰,马本玲,少腹逐瘀汤对子宫内膜容受性不良大鼠的改善作用及机制研究[J].中草药,2021; 52(5):1376-1382.
[9] 邢思思,冯冰.少腹逐瘀颗粒联合米非司酮治疗子宫内膜异位症的临床疗效观察[J].航空航天医学杂志,2021,32(12):1474-1475.
[10] 牛艳昕.少腹逐瘀颗粒联合米非司酮对子宫内膜异位症患者的临床疗效[J].中成药,2019,41(11):2812-2814.
[11] 陈绍英,于鹤.丹参酮ⅡA联合少腹逐瘀颗粒对子宫内膜异位症的疗效观察[J].中国实用医刊,2016, 43(21): 122-124.
[12] 白伶俐,闫真.少腹逐瘀颗粒联合曲普瑞林治疗子宫内膜异位症的临床研究[J].现代药物与临床,2019, 34(06): 1810-1813.
[13] 丰常申,郭伟.少腹逐瘀颗粒联合戈舍瑞林治疗子宫内膜异位症的临床研究[J].现代药物与临床,2018, 33(10): 2700-2704.
[14] 牛炜.甲羟孕酮联合少腹逐瘀颗粒治疗子宫内膜异位症的临床疗效及安全性研究[J].实用医技杂志, 2021, 28(04):516-518.
[15] 张辉,崔月美,沈雨,金仙玉.少腹逐瘀颗粒联合甲羟孕酮治疗子宫内膜异位症[J].长春中医药大学学报,2021, 37(02):365-368.